Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer

被引:19
|
作者
Scheel, Andreas H. [1 ]
Penault-Llorca, Frederique [2 ]
Hanna, Wedad [3 ]
Baretton, Gustavo [4 ]
Middel, Peter [5 ,6 ]
Burchhardt, Judith [5 ]
Hofmann, Manfred [5 ]
Jasani, Bharat [7 ]
Rueschoff, Josef [5 ,7 ]
机构
[1] Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany
[2] Ctr Jean Perrin, Dept Pathol, 58 Rue Montalembert,392, F-63011 Clermont Ferrand 1, France
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[4] Univ Hosp Dresden, Inst Pathol, Fetscherstr 74, D-01307 Dresden, Germany
[5] Inst Pathol Nordhessen, Germaniastr 7, D-34119 Kassel, Germany
[6] Univ Hosp Gottingen, Inst Pathol, Robert Koch Str 40, D-37075 Gottingen, Germany
[7] Targos Mol Pathol GmbH, Germaniastr 7, D-34119 Kassel, Germany
来源
DIAGNOSTIC PATHOLOGY | 2018年 / 13卷
关键词
HER2/neu; Immunohistochemistry; Breast cancer; Gastric cancer; Magnification rule; Predictive biomarker; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; DIGITAL IMAGE-ANALYSIS; AMERICAN-PATHOLOGISTS; PROTEIN EXPRESSION; ADENOCARCINOMAS; REPRODUCIBILITY; RECOMMENDATIONS; PEMBROLIZUMAB; VALIDATION;
D O I
10.1186/s13000-018-0696-x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for efficient anti-HER2 treatment of breast and gastric carcinomas. Immunohistochemistry (IHC) of the HER2 protein is the most common screening test, thus precise and reproducible IHC-scoring is of utmost importance. Interobserver variance still is a problem; in particular in gastric carcinomas the reliable differentiation of IHC scores 2+ and 1+ is challenging. Herein we describe the physical basis of what we called the 'magnification rule': Different microscope objectives are employed to reproducibly subdivide the continuous spectrum of IHC staining intensities into distinct categories (1+, 2+, 3+). Methods: HER2-IHC was performed on 120 breast cancer biopsy specimens (n = 40 per category). Width and color-intensity of membranous DAB chromogen precipitates were measured by whole-slide scanning and digital morphometry. Image-analysis data were related to semi-quantitative manual scoring according to the magnification rule and to the optical properties of the employed microscope objectives. Results: The semi-quantitative manual HER2-IHC scores are correlated to color-intensity measured by image-analysis and to the width of DAB-precipitates. The mean widths +/- standard deviations of precipitates were: IHC-score 1+, 0.64 +/- 0.1 mu m; score 2+, 1.0 +/- 0.23 mu m; score 3+, 2.14 +/- 0.4 mu m. The width of precipitates per category matched the optical resolution of the employed microscope objective lenses: Approximately 0.4 mu m (40x), 1.0 mu m (10x) and 2.0 mu m (5x). Conclusions: Perceived intensity, width of the DAB chromogen precipitate, and absolute color-intensity determined by image-analysis are linked. These interrelations form the physical basis of the 'magnification rule': 2+ precipitates are too narrow to be observed with 5x microscope objectives, 1+ precipitates are too narrow for 10x objectives. Thus, the rule uses the optical resolution windows of standard diagnostic microscope objectives to derive the width of the DAB-precipitates. The width is in turn correlated with color-intensity. Hereby, the more or less subjective estimation of IHC scores based only on the staining-intensity is replaced by a quasi-morphometric measurement. The principle seems universally applicable to immunohistochemical stainings of membrane-bound biomarkers that require an intensity-dependent scoring.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Targeted HER2 Treatment in Advanced Gastric Cancer
    Jorgensen, Jan Trost
    ONCOLOGY, 2010, 78 (01) : 26 - 33
  • [22] HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer
    Bae, Young Kyung
    Gong, Gyungyub
    Kang, Jun
    Lee, Ahwon
    Cho, Eun Yoon
    Lee, Ji Shin
    Suh, Kwang-Sun
    Lee, Dong Wha
    Jung, Woo Hee
    JOURNAL OF BREAST CANCER, 2012, 15 (04) : 381 - 387
  • [23] Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
    Valtorta, Emanuele
    Martino, Cosimo
    Sartore-Bianchi, Andrea
    Penaullt-Llorca, Frederique
    Viale, Giuseppe
    Risio, Mauro
    Rugge, Massimo
    Grigioni, Walter
    Bencardino, Katia
    Lonardi, Sara
    Zagonel, Vittorina
    Leone, Francesco
    Noe, Johannes
    Ciardiello, Fortunato
    Pinto, Carmine
    Labianca, Roberto
    Mosconi, Stefania
    Graiff, Claudio
    Aprile, Giuseppe
    Frau, Barbara
    Garufi, Carlo
    Loupakis, Fotios
    Racca, Patrizia
    Tonini, Giuseppe
    Lauricella, Calogero
    Veronese, Silvio
    Truini, Mauro
    Siena, Salvatore
    Marsoni, Silvia
    Gambacorta, Marcello
    MODERN PATHOLOGY, 2015, 28 (11) : 1481 - 1491
  • [24] HER2 Expression in Breast Cancer With Nonamplified HER2 and Gains of Chromosome 17 Centromere
    Panvichian, Ravat
    Tantiwetrueangdet, Anchalee
    Wongwaisayawan, Sansanee
    Nampoon, Amporn
    Lertsithichai, Panuwat
    Leelaudomlipi, Surasak
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2012, 20 (04) : 367 - 374
  • [25] HER2 testing in gastric cancer: a practical approach
    Rueschoff, Josef
    Hanna, Wedad
    Bilous, Michael
    Hofmann, Manfred
    Osamura, Robert Y.
    Penault-Llorca, Frederique
    van de Vijver, Marc
    Viale, Giuseppe
    MODERN PATHOLOGY, 2012, 25 (05) : 637 - 650
  • [26] Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings
    Gheni, Nadia
    Westenberg, David
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2020, 63 : 123 - 128
  • [27] Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients
    Sasaki, Takahide
    Fuse, Nozomu
    Kuwata, Takeshi
    Nomura, Shogo
    Kaneko, Kazuhiro
    Doi, Toshihiko
    Yoshino, Takayuki
    Asano, Hiromichi
    Ochiai, Atsushi
    Komatsu, Yoshito
    Sakamoto, Naoya
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 43 - 48
  • [28] HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
    Van Cutsem, Eric
    Bang, Yung-Jue
    Feng-Yi, Feng
    Xu, Jian M.
    Lee, Keun-Wook
    Jiao, Shun-Chang
    Chong, Jorge Leon
    Lopez-Sanchez, Roberto I.
    Price, Timothy
    Gladkov, Oleg
    Stoss, Oliver
    Hill, Julie
    Ng, Vivian
    Lehle, Michaela
    Thomas, Marlene
    Kiermaier, Astrid
    Rueschoff, Josef
    GASTRIC CANCER, 2015, 18 (03) : 476 - 484
  • [29] Evaluation of immunohistochemical staining using whole-slide imaging for HER2 scoring of breast cancer in comparison with real glass slides
    Kondo, Yuzuru
    Iijima, Tatsuo
    Noguchi, Masayuki
    PATHOLOGY INTERNATIONAL, 2012, 62 (09) : 592 - 599
  • [30] Current technologies for HER2 testing in breast cancer
    Moelans, C. B.
    de Weger, R. A.
    Van der Wall, E.
    van Diest, P. J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2011, 80 (03) : 380 - 392